Loading...
•
Mar 31, 2021
AbCellera Q1 2021 Earnings Report
Reported a significant increase in revenue driven by milestone payments and royalties, along with substantial net earnings compared to a net loss in the same quarter of the previous year.
Key Takeaways
AbCellera reported a significant increase in revenue for Q1 2021, driven by milestone payments and royalties. The company also generated substantial net earnings, a stark contrast to the net loss reported in the same quarter of the previous year. Partnership business expanded, and a second therapeutic antibody for COVID-19 advanced into clinical trials.
Total revenue increased to $203 million, up from $5 million in Q1 2020.
Net earnings reached $117 million, compared to a $2 million loss in Q1 2020.
Partnership business expanded by 16 programs, a 23% increase in growth rate.
A second therapeutic antibody for COVID-19, LY-CoV1404, advanced into clinical trials.
Revenue by Segment
Forward Guidance
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...